Insulin Resistance and Heart Failure: Molecular Mechanisms

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 609-617

  Aroor, Annayya R ^a   Mandavia, Chirag H ^a   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiac insulin resistance; Cardiorenal metabolic syndrome; Heart failure; Molecular mechanisms

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HORMONE RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NEBIVOLOL; PROTEIN TYROSINE PHOSPHATASE SHP; TRIMETAZIDINE;

ACUTE HEART FAILURE; CARDIOMYOPATHY; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERNUTRITION; REVIEW; SIGNAL TRANSDUCTION;

ADIPOKINES; CARDIO-RENAL SYNDROME; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM; FATTY ACIDS, NONESTERIFIED; HEART; HEART FAILURE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MITOCHONDRIA; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84866609821     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.005     Document Type: Review

References (55)

1. Norton C., Georgiopoulou V.V., Kalogeropoulos A.P., et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 2011, 54:78-85.
2. Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011, 1:5-12.
3. Falcão-Pires I., Leite-Moreira A.F. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012, 17(3):325-344.
4. Reaven G.M. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011, 95:875-892.
5. Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010, 55:283-293.
6. Wong C., Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007, 4:436-443.
7. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008, 51:93-102.
8. Zhang Y., Ren J. ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacol Ther 2011, 132:86-95.
9. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation 2007, 116:434-448.
10. McQueen A.P., Zhang D., Hu P., et al. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol 2005, 39:882-892.
11. Sena S., Hu P., Zhang D., et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol 2009, 46:910-918.
12. Domenighetti A.A., Danes V.R., Curl C.L., et al. Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca (2+) and proton flux dysregulation. J Mol Cell Cardiol 2010, 48:663-672.
13. Mamas M.A., Deaton C., Rutter M.K., et al. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?. J Card Fail 2010, 16:761-768.
14. Heck P.M., Dutka D.P. Insulin resistance and heart failure. Curr Heart Fail Rep 2009, 6:89-94.
15. Coats A.J., Anker S.D. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000, 35(7 Suppl 4):S9-S14.
16. Bertrand L., Horman S., Beauloye C., et al. Insulin signaling in the heart. Cardiovasc Res 2008, 79(2):238-248.
17. Saha A.K., Xu X.J., Balon T.W., et al. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?. Cell Cycle 2011, 10:3447-3451.
18. Kim J.A., Jang H.J., Martinez-Lemus L.A., et al. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012, 302:E201-E208.
19. Zhang J., Gao Z., Yin J., et al. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem 2008, 283:35375-35382.
20. Pulakat L., Aroor A.R., Gul R., et al. Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res 2012, 2012:654904. [Epub 2011 Jul 31].
21. Sowers J.R. Role of TRIB3 in diabetic and overnutrition-induced atherosclerosis. Diabetes 2012, 61:265-266.
22. Gray S., Kim J.K. New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 2011, 22:394-403.
23. Rocha V.Z., Folco E.J. Inflammatory concepts of obesity. Int J Inflamm 2011, 2011:529061. [Epub 2011 Aug 3].
24. Putnam K., Shoemaker R., Yiannikouris F., et al. The renin angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012, 302(6):H1219-H1230. [Epub 2012 Jan 6].
25. Whaley-Connell A., McCullough P.A., Sowers J.R. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med 2011, 12:21-29.
26. Lastra G., Dhuper S., Johnson M.S., et al. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol 2010, 7:577-584.
27. Kim J., Wei Y., Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008, 102:401-414.
28. Aroor A.R., Mandavia C., Ren J., et al. Mitochondria and oxidative stress in cardiorenal metabolic syndrome. Cardiorenal Med 2012, 2:87-109.
29. Cnop M., Foufelle F., Velloso L.A. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 2012, 18:59-68.
30. Lebeche D., Davidoff A.J., Hajjar R.J. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008, 5:715-724.
31. Ren J., Pulakat L., Whaley-Connell A., et al. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) 2010, 88:993-1001.
32. Mandavia C.H., Pulakat L., DeMarco V., et al. Over-nutrition, obesity and metabolic Cardiomyopathy. Metabolism 2012, Mar 30, [Epub ahead of print].
33. Tuunanen H., Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res 2011, 90:251-257.
34. Nagoshi T., Yoshimura M., Rosano G.M., et al. Optimization of cardiac metabolism in heart failure. Curr Pharm Des 2011, 17:3846-3853.
35. van de Weijer T., Schrauwen-Hinderling V.B., Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 2011, 92:10-18.
36. Boudina S., Bugger H., Sena S., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1272-1283.
37. Santos C.X., Tanaka L.Y., Wosniak J., et al. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009, 11:2409-2427.
38. Mellor K.M., Bell J.R., Young M.J., et al. Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. J Mol Cell Cardiol 2011, 50:1035-1043. [Epub 2011 Mar 6].
39. Xu X., Ren J. Unmasking the Janus faces of autophagy in obesity-associated insulin resistance and cardiac dysfunction. Clin Exp Pharmacol Physiol 2012, 39:200-208.
40. Takeda N., Manabe I. Cellular interplay between cardiac myocytes and nonmyocytes in cardiac remodeling. Int J Inflamm 2011, 13. Article ID 535241.
41. Sullivan S.D., Ratner R.E. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?. Curr Diab Rep 2011, 11:91-98.
42. Wong A.K., Al Zadjali M.A., Choy A.M., et al. Insulin resistance: a potential new target for therapy in patients with heart failure. Cardiovasc Ther 2008, 26:203-213.
43. Cittadini A., Napoli R., Monti M.G., et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012, 61(4):944-953. [Epub 2012 Feb 16].
44. Tamargo J., López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 2011, 10:536-555.
45. Messaoudi S., Azibani F., Delcayre C., et al. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012, 350:266-272.
46. Marchionne E.M., Diamond-Stanic M.K., Prasonnarong M., et al. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2012, 302:R137-R142.
47. Lastra G., Habibi J., Whaley-Connell A.T., et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009, 150:2561-2568.
48. Ladage D., Schwinger R.H., Brixius K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther 2012 Jan 26, [Epub ahead of print]. 10.1111/j.1755-5922.2011.00306.x.
49. Manrique C., Lastra G., Habibi J., et al. Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism 2011, 60:1757-1766.
50. Sivertsen J., Rosenmeier J., Holst J.J., et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012, 9(4):209-222.
51. Barnett A.H. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther 2011, 28:447-459.
52. Horowitz J.D., Chirkov Y.Y., Kennedy J.A., et al. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol 2010, 25:329-334.
53. Ardehali H., Sabbah H.N., Burke M.A., et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail 2012, 14:120-129.
54. Maack C., Böhm M. Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. J Am Coll Cardiol 2011, 58:83-86.
55. Minamino T., Komuro I., Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res 2010, 107:1071-1082.